Multus Media Financial Model

Three branded growth media products:

• Proliferum M™ - 10:1 solution, animal-free serum substitute, designed by MULTUS.
• Serum P™ - serum substitute (partial name redacted).
• Product "im A™" - serum substitute (name partially redacted).

Core value proposition: high performance, scalable/efficient, economically viable. Existing solutions use animal-derived fetal bovine serum (FBS), which is ethically problematic, costly, and not designed for food production. Multus replaces FBS with animal-free alternatives, addressing the >X% cost share that growth media represents in cultivated meat production (exact % redacted in deck).

• Alternative/cultivated meat market: $630bn by 2040, representing 35% share of the global meat industry.
• Cultivated meat CAGR 2025–2040: redacted in deck.
• Volume of growth media demanded in 2030: redacted in deck.
• Demand trajectory: Three phases shown in area chart - (1) R&D / establishing production process, (2) Scale-up + high-end restaurants, (3) Commercialisation at large scale. Market set to "explode" in 20XX (year redacted); CAGR estimate redacted.
• Consumer willingness to pay: 58% of 193 people surveyed (2019) would pay a 37% premium for cultured meat vs. conventional meat.
• Sustainability driver: 87% GHG reduction vs. conventional meat; 0 mg antibiotics.

• B2B reagent/ingredient sales: sell growth media products (Proliferum M™ and others) to cultivated meat companies for R&D and, eventually, scaled production.
• Channels: direct to cultivated meat producers and academic/research labs (inferred from stage and product type).
• Initial channel: R&D customers exist now; scale-up/high-end restaurant channel is near-term; large-scale commercialisation is long-term.
• No subscription or SaaS element apparent; pure product/volume revenue model.

• No revenue figures disclosed.
• No customer counts disclosed.
• Collaborative partnerships listed: Imperial College London, UK Research and Innovation (Innovate UK), IndieBio, Royal Academy of Engineering, SYNBICITE, EIT Climate-KIC, C/M/S Law.
• McKinsey & Co. Venture Academy consulting support.
• Cost of cultivated meat production falling: timeline shown from 2013 (per burger), 2016 (per kg), 2019 (per gram) - specific dollar values redacted.
• Industry investment to bring costs to commercial viability: bar chart of money raised ($mn) shows increasing trend through multiple years - all values redacted.

• Existing solutions use animal-derived blood serum (FBS), which was "never designed for the food industry".
• Moat framing: proprietary formulation (Proliferum M™ branded 10:1 concentrate format suggests cost/logistics advantage); animal-free, food-safe positioning differentiates from pharma-grade FBS.
• No named competitors cited in deck.

Co-founders:

• Cai Linton - CEO
• Kevin Pan - CTO
• Reka Tron - COO

Advisory board: slide present but content redacted.

Accelerators & grants: IndieBio, Royal Academy of Engineering, EIT Climate-KIC, Innovate UK.

• Archetype + why: B2B life sciences reagent / ingredient sales model (volume × price P&L). Multus sells a physical product (growth media) to other companies at volume. The right model is a bottoms-up volume/price revenue model with COGS (formulation, manufacturing, packaging), gross margin build, and a 3-statement output. Not a SaaS, marketplace, or consumer model. Closest analogy: specialty chemical / reagent company (e.g., early-stage Sigma-Aldrich-type supplier to an emerging industry).

• Forecast horizon & granularity: 5 years (2024–2028), monthly for Year 1, quarterly for Years 2–3, annual for Years 4–5. Industry commercialisation is mid-decade; model needs to capture the R&D → scale-up → commercial inflection.

• Key drivers & assumptions:
• Number of cultivated meat customer accounts - starts small (5–15 R&D labs), grows as industry scales.
• Volume per customer per period (litres of growth media) - R&D phase: low volumes (10s of litres); scale-up phase: 100s–1,000s of litres.
• ASP per litre of growth media - conventional FBS ~$300–$1,000/litre; Multus likely priced at a discount to FBS or premium for animal-free certification.
• Growth of cultivated meat industry / addressable customer base - $630bn market by 2040; CAGR redacted;.
• Gross margin - specialty reagent/media companies typically 60–75% GM at scale; early stage likely lower due to small batch manufacturing.
• Growth media share of cultivated meat production cost - stated as ">X%" (redacted); industry literature suggests ~50–80%.
• R&D / headcount - early team of 3 co-founders plus lab staff.
• Product mix - three SKUs (Proliferum M, Serum P, im A);.
• 10:1 concentrate ratio for Proliferum M - reduces shipping volume/cost, improves economics vs. dilute competitors.

• Scenarios (Base / Bull / Bear):
• Base: industry adoption of cultivated meat proceeds at moderate pace; Multus wins 10–15% of accessible early market; reaches £5–10M revenue by Year 5.
• Bull: cultivated meat regulatory approval accelerates in UK/EU/Singapore; multiple large food companies contract Multus as exclusive supplier; pricing power maintained.
• Bear: cultivated meat industry stalls (regulatory/consumer), compressing demand; large pharma suppliers (e.g., Merck/Sigma) enter with competing animal-free products; Multus squeezed on price.
• Flex variables: customer acquisition pace, ASP, gross margin trajectory, industry CAGR.

• Required sheets / outputs:

1. Assumptions - all drivers, scenarios toggleable.
2. Revenue build - customers × volume × price, by product SKU.
3. COGS & gross margin - manufacturing cost per litre, scaling curve.
4. OpEx - R&D, headcount, G&A.
5. Income Statement (P&L).
6. Cash flow - burn rate and runway (critical for fundraising context).
7. Balance sheet (simple: cash, inventory, AR/AP).
8. Funding / runway - how long does the raise last at different burn rates.
9. Sensitivity table - GM% and ASP vs. revenue/EBITDA.